TELUS International Acquires Playment, Firmly Staking Its Leadership in the Global Data Annotation Market
TELUS International (NYSE and TSX: TIXT), a leading digital customer experience (DCX) innovator that designs, builds and delivers next-generation solutions for global and disruptive brands, today announced the acquisition of Bangalore-based Playment, a leader in data annotation and computer vision tools and services specialized in 2D and 3D image, video and LiDAR (light detection and ranging) - a remote sensing method that uses laser pulses to measure variable distances. The acquisition follows TELUS International’s recent purchase of Lionbridge AI and builds upon the company’s existing deep domain expertise and experience in data annotation, uniquely positioning TELUS International to support technology and large enterprise clients developing AI-powered solutions across a variety of vertical markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210706005219/en/
“We are very excited to welcome Playment and its highly engaged, world-class product and engineering team to our TELUS International family today. The acquisition will meaningfully accelerate our company’s computer vision capabilities and further bolster our position at the forefront of our global peers with respect to technology innovation, strategy excellence and talent,” said Jeff Puritt, president and CEO of TELUS International. “As one of the key enabling technologies for today’s advanced AI applications, computer vision is among the most revolutionary technologies of our generation with applications across every sector of the economy. The technology has become increasingly valuable to tech firms and the wider market as brands seek to uncover solutions for scenarios that typically require complex human judgement from visual and spatial patterns to solve nuanced business challenges, and build innovative, market-leading smart products and services.”
The computer vision market is forecast to grow from nearly $16 billion in 2021 to more than $50 billion by 2026, according to an analysis by MarketsandMarkets. The technology is disrupting entire industries and driving transformational societal changes from supporting diagnoses in healthcare, to reducing fraud in banking, to improving e-commerce experiences through enhanced visual search features. In agriculture, for example, advanced farming processes powered by computer vision and AI can provide early and accurate detection and diagnosis of plant diseases based on a green-color ratio and other visual cues to reduce losses in crop yields. In harvesting, computer vision and AI systems can automatically grade and sort food items based on trained parameters, for example, in one fruit detection method, color cameras identify apples on trees that are ready to be picked, and additional stereo cameras detect their relative position for automatic harvesting by a robotic vacuum.
“Standing still is not an option for any company in any industry, but developing and powering the innovations of tomorrow requires a large and continuous supply chain of high-quality image and video training data, which also happens to be the most significant bottleneck in AI development,” shared Puritt. “With the addition of Playment’s expertise, ingenuity and proprietary data annotation platform, TELUS International is more strongly positioned than ever to meet our clients’ current and future needs to support their ongoing growth and evolution. As we continue to expand and evolve as a team and as a company, our focus will remain on empowering our clients to meet the accelerated pace of change in today’s digital world and creating long-term value for our clients, shareholders, team members and the communities where we operate.”
Playment was founded in 2015 and received funding from Elevation Capital (formerly SAIF Partners) and Y Combinator in the early phases of its development. Playment provides fully managed data annotation services that include AI strategy consulting and a SaaS-based platform that transforms videos and images into high-quality annotated data to support a broad range of use cases, ranging from computer vision and data categorization to search relevance. With a focus on data security, user experience and efficiency, and by engaging India’s largest on-demand skilled and secure workforce, Playment has established a hyper-productive environment that delivers datasets faster than its competitors.
“We are thrilled to embark upon the exciting journey ahead with the TELUS International team to harness the full potential of computer vision technology and to advance our joint mission of expediting the AI age through our many partnerships with brands around the world,” said Siddharth Mall, co-founder and CEO of Playment. “We look forward to growing our engagements with existing clients and having the opportunity to work with others that are currently supported by TELUS International to demonstrate the art of the possible through our complementary add-on image, video and LiDAR data annotation capabilities and computer vision expertise. By amplifying our R&D efforts to further extend our product leadership in the industry, and leveraging TELUS International’s global presence to accelerate our go-to-market strategy, together we will help drive disruption across all industry verticals, including in automotive, retail, Internet of Things (IoT), financial services, healthcare, and agriculture.”
TELUS International operates in more than 25 countries around the world with a diverse, multilingual team of more than 50,000 team members, and a global AI Community of more than one million trained data annotators and linguists spread across six continents. To learn more about TELUS International AI Data Solutions, visit www.telusinternational.com.
About TELUS International
TELUS International (NYSE and TSX: TIXT) designs, builds and delivers next-generation digital solutions to enhance the customer experience (CX) for global and disruptive brands. The company’s services support the full lifecycle of its clients’ digital transformation journeys and enable them to more quickly embrace next-generation digital technologies to deliver better business outcomes. TELUS International’s integrated solutions and capabilities span digital strategy, innovation, consulting and design, digital transformation and IT lifecycle solutions, data annotation and intelligent automation, and omnichannel CX solutions that include content moderation, trust and safety solutions and other managed solutions. Fueling all stages of company growth, TELUS International partners with brands across high growth industry verticals, including tech and games, communications and media, eCommerce and fintech, healthcare, and travel and hospitality. Learn more at: www.telusinternational.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005219/en/
Contact information
Media Relations:
Ali Wilson
(604) 328-7093
ali.wilson@telusinternational.com
Investor Relations:
Jason Mayr
(604) 695-3455
ir@telusinternational.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom